

# Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

NCT04005976

---

**Status** RECRUITING  
**Sponsor** The University of Texas Health Science Center, Houston  
**Enrollment** 5,000 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Patients and their relatives with a confirmed pathogenic, likely pathogenic variant, or variant of unknown clinical significance in at least one of the H-TAD genes (i.e. TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLK, PRKG1, MAT2A, MFAP5, LOX, COL3A1, FOXE3, and FBN1).
- Patients of all ages, sex and race for which informed consent can be obtained.

### Exclusion (1)

- Patients without a confirmed causative variant for H-TAD.

## Locations (20 total)

---

HOAG memorial hospital presbyterian, Newport Beach, California, United States  
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States  
Sutter Health, Sacramento, California, United States  
... and 17 more locations

---

<https://clinicaltrials.gov/study/NCT04005976>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.